• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by BlackRock Technology and Private Equity Term Trust

    5/11/26 3:32:46 PM ET
    $BTX
    Get the next $BTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    BlackRock Technology & Private Equity Term Trust

    (Name of Issuer)


    Common Shares

    (Title of Class of Securities)




    09260Q108

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    09260Q108


    1Names of Reporting Persons

    Morgan Stanley
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    779,668.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,199,221.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,199,221.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    HC, CO


    SCHEDULE 13G

    CUSIP Number(s):
    09260Q108


    1Names of Reporting Persons

    Parametric Portfolio Associates LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    779,668.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,199,221.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,199,221.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    IA, CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BlackRock Technology & Private Equity Term Trust
    (b)Address of issuer's principal executive offices:

    BELLEVUE PARKWAY, WILMINGTON, DE, 19808
    Item 2. 
    (a)Name of person filing:

    1: Morgan Stanley 2: Parametric Portfolio Associates LLC
    (b)Address or principal business office or, if none, residence:

    1: 1585 Broadway, New York, NY 10036 ;2: 800 Fifth Avenue, Suite 2800, Seattle, WA 98104
    (c)Citizenship:

    1: Delaware 2: Delaware
    (d)Title of class of securities:

    Common Shares
    (e)CUSIP Number(s):

    09260Q108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    5.3  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit 99.2
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Morgan Stanley
     
    Signature:Claire Gordon
    Name/Title:Authorized Signatory, Morgan Stanley
    Date:05/11/2026
     
    Parametric Portfolio Associates LLC
     
    Signature:Cindy Kim
    Name/Title:Authorized Signatory, Parametric Portfolio Associates LLC
    Date:05/11/2026
    Exhibit Information

    EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

    Get the next $BTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTX

    DatePrice TargetRatingAnalyst
    12/29/2021$9.00Overweight
    Cantor Fitzgerald
    10/6/2021$20.00Buy
    Maxim Group
    More analyst ratings

    $BTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Brooklyn with a new price target

    Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00

    12/29/21 7:03:49 AM ET
    $BTX

    Maxim Group initiated coverage on Brooklyn ImmunoTherapeutics with a new price target

    Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00

    10/6/21 7:53:44 AM ET
    $BTX

    $BTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Portfolio Manager Menge Steven Reid

    4 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)

    2/3/26 7:50:32 PM ET
    $BTX

    SEC Form 4 filed by Portfolio Manager Kim Tony

    4 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)

    2/3/26 7:27:17 PM ET
    $BTX

    Director Fairbairn Robert W sold $143,027 worth of shares (21,937 units at $6.52), closing all direct ownership in the company (SEC Form 4)

    4 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)

    12/22/25 5:21:02 PM ET
    $BTX

    $BTX
    SEC Filings

    View All

    SEC Form DEF 14A filed by BlackRock Technology and Private Equity Term Trust

    DEF 14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

    6/2/26 4:34:13 PM ET
    $BTX

    SEC Form SCHEDULE 13G filed by BlackRock Technology and Private Equity Term Trust

    SCHEDULE 13G - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)

    5/11/26 3:32:46 PM ET
    $BTX

    SEC Form N-CEN filed by BlackRock Technology and Private Equity Term Trust

    N-CEN - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

    3/13/26 4:12:15 PM ET
    $BTX

    $BTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

    Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

    5/29/26 4:31:00 PM ET
    $BBN
    $BCAT
    $BCX
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable

    Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

    Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

    4/30/26 4:30:00 PM ET
    $BBN
    $BCAT
    $BCX
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable

    Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capi

    3/31/26 4:44:00 PM ET
    $BBN
    $BCAT
    $BCX
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable

    $BTX
    Leadership Updates

    Live Leadership Updates

    View All

    Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

    SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief

    5/31/22 7:30:00 AM ET
    $BTX

    Amarin Announces Appointment of New Directors and Board Leadership Changes

    Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta

    5/19/22 8:23:13 AM ET
    $AMRN
    $BTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

    NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati

    1/20/22 7:30:00 AM ET
    $BTX

    $BTX
    Financials

    Live finance-specific insights

    View All

    Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

    Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

    5/29/26 4:31:00 PM ET
    $BBN
    $BCAT
    $BCX
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable

    Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

    Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

    4/30/26 4:30:00 PM ET
    $BBN
    $BCAT
    $BCX
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable

    Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capi

    3/31/26 4:44:00 PM ET
    $BBN
    $BCAT
    $BCX
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable

    $BTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

    SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

    1/31/24 7:05:56 AM ET
    $BTX

    SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

    SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

    1/19/24 10:31:54 AM ET
    $BTX

    SEC Form SC 13D/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

    SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)

    12/22/23 12:05:20 PM ET
    $BTX